Study of survivors of nasopharyngeal cancer in youth
Part of Cancer clinical trials.
This study follows children and teenagers who had nasopharyngeal cancer (cancer in the upper part of the throat behind the nose) to better understand outcomes after treatment. It may help doctors learn what long-term follow-up is needed for survivors and their families.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your sibling) must agree in writing to join this study and understand it is experimental
- You must have been diagnosed with non-keratinizing nasopharyngeal cancer before age 21
- Your diagnosis should have been confirmed by pathology (exam of tissue samples)
- You must not already be enrolled in another blinded (placebo/secret) clinical trial
- The study team must be able to get your tumor response and survival information
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the immune system responds to radiation therapy for nasopharyngeal cancer. It will use scans and blood tests to find markers that might predict how well treatment works.
This study looks at how well the current cancer staging system works for nasopharyngeal cancer. If you have been diagnosed with this type of cancer between October 2025 and September 2026, you may be able to join.
This study looks at the molecular features of nasopharyngeal carcinoma to find better ways to predict treatment success and identify new targets for therapy. It’s for people already treated at Union Hospital in Wuhan.
This trial tests if adding an immunotherapy drug (toripalimab) to standard chemotherapy works better than chemotherapy alone for children and teens with advanced nasopharyngeal cancer (a type of nose cancer). The goal is to improve outcomes for newly diagnosed patients.
This study looks at how well nasopharyngeal cancer (NPC) responds to the first round of chemotherapy before other treatments. It aims to see if the amount of tumor shrinkage can help predict outcomes and guide future care for people with advanced NPC.
This trial tests combining the immunotherapy drug nivolumab with standard chemotherapy to treat newly diagnosed nasopharyngeal cancer in children and young adults. The goal is to see if adding this immune-boosting medicine can help shrink tumors and prevent the cancer from coming back.
Hear when a new NPC Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.